Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea

Nordic Pharma

Status: Completed

Conditions: Medical Termination of Pregnancy

Study type: Observational

Funder types: Industry

Identifiers

NCT02614781

RYMMA

Details and patient eligibility

About

This study is a non-interventional prospective, multicenter, longitudinal study conducted in France, among a representative sample of public and/or private birth control centers.

The aim of the study is to assess, in real-life settings, the success rate of the protocol Mifegyne / prostaglandin analogue in patients asking for medical abortion either prior or beyond 7 weeks of amenorrhea.

Enrollment: 892 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult women (≥ 18 years old) with confirmed intra-uterine pregnancy consulting for medical termination of pregnancy
• Patients for whom the physician decides to use a Mifegyne 600 mg and prostaglandin analogue combination for medical abortion
• Patients agreeing to participate in the study after having been informed orally by the physician and given the information sheet
• Informed patients accepting the computer processing of their medical data and their right of access and correction

Exclusion criteria

• Patients with known hypersensitivity to mifepristone
• Patients with known hypersensitivity to prostaglandin analogues (misoprostol or gemeprost).
• Patients with severe and progressive disease
• Patients with ectopic pregnancy